Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘platinum resistant ovarian cancer’

One of the joys of oncology research is that it’s data driven, which means companies can quite clearly see how others have fared, and where the gaps and opportunities lie for new product development.

There is always the potential to unlock the gates to the “secret garden,” whether it be targeting a tumour type previously considered intractable, treating an unmet medical need where there are few or no effective therapies, or in the case of immuno-oncology, manipulating the tumour microenvironment in a way that leads to an improvement in the long tail of survival we’re all looking for.

In addition to improved outcomes, you also need a safety profile with a favourable benefit/risk ratio, where there aren’t intolerable or life changing side effects or an increased risk of death. Who said it was easy?

Innovation takes many forms, and in this post we’re looking at how one biotech company may have unlocked the key to a secret garden through the optimised design of their molecule.  As always, it’s early days although it’s good to see companies looking to solve hard problems because the easy low hanging fruit wins in immuno-oncology went a long time ago.

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Last month’s Biotech Strategy mailbag – where we answer questions from subscribers – turned out to be rather controversial with strong feelings running in several camps on Puma Biotech’s neratinib in breast cancer.

This time around we have a bunch of questions on completely different topics and compounds to cover:

  • BRAF plus MEK and/or immunotherapy in BRAFV600 metastatic melanoma
  • Immunogen’s IMGN853 – now known as mirvetuximab soravtansine – in platinum resistant ovarian cancer
  • AbbVie/Genentech’s ABT–199/GDC–0199 venetoclax

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

error: Content is protected !!